01—Abstract
Summary
Summary of the 10-K filed March 21, 2002. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 2001 10-K shows a company with steady, profitable growth but slowing top-line momentum.
Revenue rose 5% to $386.1 milliona in 2001 (from $367.4 million), while net income climbed 3% to $37.6 million and diluted EPS reached $1.09 (up from $1.02). Gross margin held near 47%, and operating income grew 6% to $56.6 million. Growth was concentrated in the Companion Animal Group (CAG, +4% to $308.0 million) and the Food and Environmental Division (FED, +9% to $78.0 million), with water testing and veterinary reference labs as the main drivers.
Management acknowledges that the growth rate of certain products has declined over several years, and CAG's gross margin slipped to 45% due to fixed-cost under-absorption from delayed product launches. The balance sheet strengthened, with stockholders' equity rising to $301.7 millionb and operating cash flow of $46.4 million funding $17.4 million of capex and $13.0 million of share buybacks. Cash and short-term investments were $79.6 million, plus $21.0 million in long-term investments, and the company carries only $8.4 million of notes payable.
Inventory rose sharply to $86.2 millionc, driven by VetTest slide purchase commitments, LaserCyte hematology development costs, and $8.6 million of nitazoxanide raw materials tied to a pending FDA approval. Total unconditional purchase obligations of $299.4 million through 2010 represent a notable fixed commitment.
Key forward-looking items include the planned second-half 2002 launch of the LaserCyte hematology system (which management expects to raise warranty expense significantly), the FDA review of nitazoxanide, a CEO transition to Jonathan Ayers in January 2002 with a roughly $3.0 milliond related charge, and the adoption of SFAS 142, which will eliminate about $4.3 million of goodwill amortization in 2002 and requires an impairment review. Management does not currently expect an impairment charge.
02—Key points
Key Highlights
- Revenue grew 5% to $386.1 million in 2001, with CAG up 4% to $308.0 million and FED up 9% to $78.0 million.
- Diluted EPS rose to $1.09 from $1.02 (+7%), helped by a 4% reduction in diluted share count to 34.6 million from 36.1 million through buybacks.
- Operating income increased 6% to $56.6 million, but CAG gross margin fell to 45% from 46% due to fixed-cost under-absorption from product launch delays.
- Strong cash generation: operating cash flow of $46.4 million, $79.6 million in cash and short-term investments, plus $21.0 million in long-term investments against only $8.4 million of debt.
- Inventory rose 31% to $86.2 million, reflecting contractual VetTest slide purchases, LaserCyte development inventory, and $8.6 million of nitazoxanide materials contingent on FDA approval.
- Large fixed purchase commitments of $299.4 million through 2010, principally for VetTest slides from Ortho-Clinical Diagnostics and products from Becton Dickinson.
- Leadership transition: Jonathan Ayers succeeded founder David Shaw as CEO in January 2002, triggering a roughly $3.0 million pre-tax charge in Q1 2002.
03—Questions
Frequently Asked Questions
How did IDEXX perform financially in 2001?
IDEXX grew revenue 5% to $386.1 million and net income 3% to $37.6 million. Diluted EPS increased to $1.09 from $1.02, aided by share repurchases that reduced the diluted share count. Operating margin was about 14.6%, roughly flat with the prior year.
What are the main growth drivers and risks?
Growth came from veterinary reference laboratory services (including the 2000 VPS acquisition), canine test kits such as the SNAP 3Dx, ACAREXX ear-mite treatment, and water testing products including Genera's cryptosporidia tests. Risks include declining growth rates in certain products, intense competition from larger firms, dependence on single-source suppliers, and pending FDA approval of the nitazoxanide drug.
What should investors watch in 2002?
Key items include the LaserCyte hematology launch in the second half of 2002 (with expected warranty cost increases), FDA action on the nitazoxanide product whose $8.6 million of inventory could be impaired if rejected, the goodwill impairment review under SFAS 142 (no charge currently expected), and the CEO transition costs. The 2002 capital budget is about $17.0 million.
Is the balance sheet healthy?
Yes. Stockholders' equity rose to $301.7 million, working capital to $164.2 million, and total debt is just $8.4 million, mostly notes tied to the Genera acquisition. The company has a $20.0 million uncommitted bank credit line, which was unused at year-end. Rising inventory and long-term purchase commitments are the main balance-sheet watch points.
Are there any material legal proceedings or customer concentration issues?
The company reports no material legal proceedings, though it has received third-party patent infringement notices regarding immunoassay products. No customer accounted for 10% or more of sales in 2000 or 2001 (in 1999, Butler Company represented 10%). International revenue was 28% of the total.
04—Continue